Investment Rating - The report indicates a positive investment outlook for the agriculture, forestry, animal husbandry, and fishery sector, highlighting significant profit growth across various sub-sectors [2][11]. Core Insights - The agriculture, forestry, animal husbandry, and fishery sector achieved a substantial year-on-year profit increase of 208% in the first half of 2025, with total net profit reaching 207.8 billion yuan [2][11]. - The sub-sectors with the highest profit growth included seed industry (+1212%), pig farming (+663%), and agricultural product processing (+60%) [2][11]. - The report emphasizes the recovery of profitability in pig farming, driven by improved cost efficiency and increased production volume, despite a slight decline in pig prices [2][17]. - The poultry sector, particularly white feathered chicken, is experiencing pressure due to oversupply and weak demand, while yellow feathered chicken prices have significantly dropped [2][17]. - The pet food industry is noted for its continued growth, with domestic brands gaining market share and profitability, despite challenges in export due to increased tariffs [2][3]. Summary by Sections 1. Overview of the Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The sector's net profit for H1 2025 was 207.8 billion yuan, marking a 208% increase year-on-year [11]. - The second quarter of 2025 also showed a profit increase of 26% compared to the previous year, with notable growth in agricultural product processing and pig farming [15]. 2. Sub-sector Performance 2.1 Pig Farming - The pig farming sector reported a total revenue of 201.9 billion yuan in H1 2025, a 17.9% increase year-on-year, with net profit soaring to 159.24 billion yuan, up 866% [2][17]. - Despite a slight decline in pig prices, the sector benefited from increased production and reduced costs, leading to significant profit improvements [2][17]. 2.2 Poultry Farming - The white feathered chicken sector is stabilizing, with a slight recovery in profitability due to cost improvements, while the yellow feathered chicken sector faces significant price declines [2][17]. 2.3 Pet Food - The pet food sector saw a revenue increase of 21.4% in H1 2025, driven by domestic brand growth and improved profitability [2][3]. 2.4 Animal Health - The animal health sector experienced a revenue increase of 26.44% in H1 2025, with net profit rising by 68.35% [4]. 2.5 Feed - The feed sector reported a revenue increase of 13.3% in H1 2025, with net profit up 29.5% [4]. 2.6 Seed Industry - The seed industry faced challenges with a revenue decline of 9.7% in H1 2025, attributed to falling grain prices [4]. 3. Investment Analysis - The report suggests that the pig farming industry is entering a phase of stable, high-quality development, with potential for significant profit stability and valuation reassessment for leading companies [3][5]. - The pet food sector is expected to continue its long-term growth trajectory, supported by increasing pet ownership and spending [3][5].

Market Overview - On September 19, the animal health sector declined by 0.26% compared to the previous trading day, with the driving force leading the decline [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable stock movements included: - *ST Lvkang (002868): Closed at 27.56, up 4.99% with a trading volume of 38,500 shares and a turnover of 105 million yuan [1] - Kexin Biological (688526): Closed at 18.08, up 0.39% with a trading volume of 22,700 shares and a turnover of 40.94 million yuan [1] - Driving Force (838275): Closed at 10.50, down 4.11% with a trading volume of 21,200 shares and a turnover of 22.63 million yuan [2] Capital Flow - The animal health sector experienced a net outflow of 91.4 million yuan from institutional investors, while retail investors saw a net inflow of 70.15 million yuan [2] - The capital flow for individual stocks showed: - RuiPu Biological (300119): Net inflow of 16.56 million yuan from institutional investors, but a net outflow of 21.57 million yuan from retail investors [3] - *ST Lvkang (002868): Net inflow of 6.13 million yuan from institutional investors, with a net outflow of 4.21 million yuan from retail investors [3]

Investment Rating - The report maintains a positive outlook on the agriculture, forestry, animal husbandry, and fishery industry, indicating a "Buy" rating for the sector [2]. Core Insights - In the first half of 2025, the listed companies in the livestock sector experienced a significant recovery in profitability, with a total net profit of 20.78 billion yuan, representing a year-on-year increase of 208% [3][14]. - The sub-industries with the highest profit growth included seed industry (+1212%), pig farming (+663%), and agricultural product processing (+60%) [3][15]. - The report highlights a notable divergence in performance among companies within the sector, driven by industry dynamics and operational conditions [3]. Summary by Sections 1. Overview of the Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The agriculture, forestry, animal husbandry, and fishery sector's net profit for the first half of 2025 reached 20.78 billion yuan, a substantial increase of 208% year-on-year [14]. - The second quarter of 2025 also showed a continued growth trend, with a net profit of 10.84 billion yuan, up 26% year-on-year [18]. 2. Sub-sector Performance Review and Investment Strategy 2.1 Pig Farming - The pig farming sector reported a total revenue of 201.9 billion yuan in the first half of 2025, a year-on-year increase of 17.9%, with net profit reaching 15.92 billion yuan, up 865.5% [21]. - Despite a slight decline in pig prices, companies improved profitability through increased volume and reduced costs, with average breeding costs down by 7.2% [21][33]. 2.2 Poultry Farming - The white feather chicken segment showed signs of stabilization, with revenue growth of 0.6% year-on-year, while the yellow feather chicken segment faced significant price declines, leading to a sharp drop in profitability [3][21]. 2.3 Pet Food - The pet food sector saw a revenue increase of 21.4% year-on-year, driven by domestic brand growth and a favorable pricing environment [3][21]. 2.4 Animal Health - The animal health sector experienced a recovery in demand, with total revenue of 8.61 billion yuan, reflecting a year-on-year increase of 26.44% [5][21]. 2.5 Feed - The feed sector's revenue reached 81.91 billion yuan, up 13.3% year-on-year, benefiting from improved profitability in livestock farming [5][21]. 2.6 Seed Industry - The seed industry faced challenges with a revenue decline of 9.7% year-on-year, attributed to falling grain prices and reduced planting enthusiasm among farmers [5][21]. 3. Investment Analysis and Recommendations - The report suggests that the pig farming industry is entering a phase of stable, high-quality development, with potential for significant profit recovery and valuation reassessment for leading companies [4][6]. - The pet food sector is expected to maintain strong growth, supported by increasing pet ownership and spending per pet [4][6].

Market Overview - The animal health sector experienced a decline of 0.32% on September 17, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Individual Stock Performance - ST Lvkang (002868) saw a closing price of 25.00, with a rise of 5.00% and a trading volume of 28,300 lots, totaling a transaction value of 67.72 million [1] - Ruipu Biological (300119) closed at 22.06, up 0.32%, with a trading volume of 78,100 lots and a transaction value of 172 million [1] - Kexin Biological (688526) closed at 18.39, with a slight increase of 0.05% and a trading volume of 30,000 lots, totaling 55.44 million [1] - Other notable declines include Yongshun Biological (10.40, -0.19%), Zhongmu Co. (7.38, -0.27%), and Haili Biological (7.15, -0.28%) [1] Capital Flow Analysis - The animal health sector saw a net outflow of 72.39 million from institutional investors, while retail investors contributed a net inflow of 31.00 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Detailed Capital Flow for Selected Stocks - Ruipu Biological had a net inflow of 3.75 million from institutional investors, but a net outflow of 5.98 million from retail investors [3] - ST Lvkang experienced a net inflow of 2.05 million from institutional investors, with retail investors showing a slight outflow [3] - Shunlian Biological faced a significant net outflow of 20.09 million from institutional investors, while retail investors contributed a net inflow of 13.17 million [3]

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]

Group 1 - The core viewpoint of the article highlights significant target price increases for certain companies, with Hanwang Technology leading at a rise of 79.86% [1] - Other companies with notable target price increases include Ruipubio at 64.51% and Xindian Software at 60.09%, all belonging to the software development and animal health sectors [1] - On September 15, a total of 94 companies received broker recommendations, with notable mentions including Shanying International, Huachao City A, and Hayao Co., each receiving one recommendation [1] Group 2 - On the same date, three companies had their ratings downgraded, including Tongwei Co., which was downgraded from "Buy" to "Hold" by Tianfeng Securities [1] - Other downgrades included Focus Technology from "Buy" to "Hold" by Huatai Financial Holdings (Hong Kong) and Beijing Junzheng from "Buy" to "Hold" by Zhongyou Securities [1] - Additionally, five companies received initial coverage from brokers, with Jin Feng Technology receiving a "Recommended" rating from Minsheng Securities [1]

Investment Rating - The industry investment rating is "Positive" [3] Core Viewpoints - The report highlights that the agricultural sector is experiencing a recovery, with specific segments such as the pig and beef industries showing signs of improvement. Cost reduction and efficiency enhancement are key drivers for performance improvement in the pig sector, while the beef sector is witnessing a rebound from a cyclical low [6][7][47]. Summary by Sections 1. Pig Industry - The pig sector has shown significant improvement in performance, with 15 listed pig companies achieving a revenue of 196.98 billion yuan in the first half of 2025, a year-on-year increase of 19%. The net profit attributable to shareholders reached 16.33 billion yuan, up 625% year-on-year [9]. - The average pig price has been under pressure, dropping to a low of 13.96 yuan/kg in June 2025. However, leading companies like Muyuan and Wens continue to maintain high profitability per head due to their efficiency advantages [15][42]. - Recommendations include focusing on low-cost, high-certainty leaders such as Muyuan and Wens, as well as high-growth small pig companies like Shennong Group and Juxing Agriculture [7][43]. 2. Beef Industry - The beef sector is experiencing a cyclical recovery, with live cattle prices increasing significantly since mid-February 2025. As of September 8, 2025, the prices for fattened bulls, calves, and cull cows have risen by 2.39, 8.33, and 3.18 yuan/kg respectively [47]. - The report notes that the overall beef market is supported by a trend towards protein upgrading, which is expected to continue despite economic fluctuations [57]. 3. Animal Health Sector - The animal health sector is stabilizing, with a focus on the development of pet business. The rapid release of pet vaccines is anticipated to enhance valuations across companies [7]. 4. Seed Industry - The seed market is shifting from quantity to quality competition, with a focus on superior varieties as the core competitiveness of seed companies. The report emphasizes the importance of resource integration and mergers in the seed industry [7]. Companies with strong variety reserves, such as Dabeinong and Longping High-Tech, are expected to benefit [7].

Core Insights - The animal health sector experienced a 1.14% increase on September 15, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - BioShares (600201) closed at 8.82, up 7.17% with a trading volume of 624,100 shares and a turnover of 539 million yuan [1] - Dayu Biological (871970) closed at 11.50, up 6.09% with a trading volume of 124,300 shares and a turnover of 139 million yuan [1] - Other notable performers include: - Jinhai Biological (002688) at 7.20, up 3.00% [1] - Ruipu Biological (300119) at 21.98, up 1.76% [1] - Zhongmu Co. (600195) at 7.50, up 1.63% [1] Capital Flow - The animal health sector saw a net outflow of 25.577 million yuan from institutional investors, while retail investors contributed a net inflow of 6.5625 million yuan [2] - The capital flow for individual stocks indicates: - Jinhai Biological had a net inflow of 32.1651 million yuan from institutional investors [3] - Zhongmu Co. had a net inflow of 6.8986 million yuan from institutional investors [3] - Ruipu Biological experienced a net outflow of 1.1475 million yuan from institutional investors [3]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 8.96 CNY over the next six months, up from the previous rating [1][10]. Core Insights - The company has shown significant performance recovery, with a notable increase in revenue and net profit driven by its pet business and ongoing research and development efforts [1][7]. - The revenue for the first half of 2025 reached 2.793 billion CNY, reflecting a year-on-year growth of 12.63%, while the net profit attributable to the parent company was 82 million CNY, up 30.19% year-on-year [7]. - The company is focusing on large customer development and synergistic services in the animal health sector, which is expected to enhance its profitability [7]. Financial Performance Summary - Revenue projections for 2024A, 2025E, 2026E, and 2027E are 6,017 million CNY, 6,569 million CNY, 7,190 million CNY, and 7,798 million CNY respectively, with growth rates of 11.30%, 9.17%, 9.46%, and 8.46% [2][9]. - The net profit attributable to the parent company is forecasted to be 71 million CNY in 2024A, increasing to 287 million CNY in 2025E, 351 million CNY in 2026E, and 386 million CNY in 2027E, with growth rates of -82.41%, 305.33%, 22.12%, and 9.99% respectively [2][9]. - The company’s earnings per share (EPS) are projected to be 0.07 CNY in 2024A, rising to 0.28 CNY in 2025E, 0.34 CNY in 2026E, and 0.38 CNY in 2027E [2][9]. Business Segment Performance - The pharmaceutical segment reported strong performance with sales revenue of 999 million CNY, while the biological products segment faced a decline in revenue to 450 million CNY due to increased competition [7]. - The feed segment generated revenue of 536 million CNY, indicating stable performance despite some pricing pressures [7]. - The company is actively investing in the pet health product market, with significant advancements in product development and brand promotion [7]. Research and Development - The company invested 60 million CNY in R&D in the first half of 2025, representing a year-on-year increase of 4.73%, with a research expense ratio of 2.14% [7]. - The company is focusing on developing vaccines and pharmaceuticals for pets, with several new products launched during the reporting period [7]. Valuation and Market Position - The company is valued at a PE ratio of 32 times for 2025, which is competitive compared to its peers in the animal health industry, which have an average PE of 31 times [10][11]. - The company’s market capitalization is approximately 7.577 billion CNY, with a total asset value of 8.882 billion CNY [5].

Group 1 - The company announced on September 12 that it has incorporated cost reduction targets into its budget through a closed-loop management of all cost elements, aiming to achieve cost reduction and efficiency improvement [2] - The core focus of the company is "value-driven," and it is fully committed to advancing lean transformation and implementing a comprehensive closed-loop operational management system [2] - The company is concentrating on four key areas: centralized procurement, process optimization, lean management, and workforce efficiency, to reshape its profit model through lean cost reduction and value innovation [2] Group 2 - The company has achieved significant results in enhancing production management levels, supply chain efficiency, and product quality through its initiatives [2]